A single centre experience of erlotinib in unselected and wild type EGFR patients with non small cell lung cancer

被引：0
|
作者：
Walter, H. S. [1 ]
Ahmed, S. I. [1 ]
机构：
[1] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
来源：
LUNG CANCER | 2013年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [1] The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Tanabe, Tsuyoshi
    Tsushima, Kenji
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Kubo, Keishi
    Koyama, Shigeru
    Ooura, Nariaki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S690 - S690
  • [2] A single centre experience of gefitinib in patients with EGFR mutation positive non small cell lung cancer
    Walter, H. S.
    Fennell, D. A.
    Ahmed, S. I.
    [J]. LUNG CANCER, 2013, 79 : S7 - S7
  • [3] EGFR Mutations in Non Small Cell Lung Cancer Patients: Single Centre Experience from India
    Choughule, A. B.
    Prabhash, K.
    Thavamani, A.
    Desai, S.
    Joshi, A.
    Noronha, V.
    Banavali, S.
    Jambhekar, N.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 701 - 701
  • [4] Erlotinib and docetaxel in relapsed non-small cell lung cancer: a single centre experience
    Hook, J.
    MacDermott, C.
    Cheeseman, S.
    [J]. LUNG CANCER, 2009, 63 : S8 - S8
  • [5] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [6] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
  • [7] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Braun, Eduardo
    Bonomi, Philip
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
  • [8] EGFR and EMIA-Alk testing for non-small cell lung cancer patients a single centre experience
    Chatterjee, S.
    Arora, N.
    Parihar, M.
    Midha, D.
    Mukherjee, G.
    Dabkara, D.
    Biswas, B.
    Mishra, D.
    Shrimali, R.
    [J]. LUNG CANCER, 2016, 91 : S4 - S4
  • [9] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    [J]. BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
  • [10] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
12345